Novavax, Inc. (NVAX) Stock

About Novavax, Inc.

Novavax, Inc. (NVAX) stock trades at $9.70 with a market capitalization of $1.60B. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.24, reflecting a net loss over the last twelve months, a negative price-to-book of -9.50, reflecting negative shareholders' equity, price-to-sales of 4.39. Over the past 52 weeks the stock has ranged between $6.20 and $13.39, and currently trades 27.6% below its 52-week high.

On profitability, Novavax, Inc. generates a return on equity (ROE) of 159.85% (not meaningful, as shareholders' equity is negative), return on capital employed of -36.37%, an operating margin of 50.13%, a net profit margin of -59.87%.

Novavax, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Novavax, Inc. reported revenue of $15.0M rising to $1.1B, a change of +7386.7% across 10 years. Compounded, revenue has grown 119.6% a year over five years, -11.1% over three, 64.7% over the last twelve months. Net profit rose to $440.0M.

Operating margin went from -1752.8% in 2016 to 50.1% in 2025, a gain of 1803.0 percentage points. The most recent net margin is -59.87%. On a trailing twelve-month basis to Jun '26, revenue is $414.0M and net profit $-246.0M.

Borrowings fell from $316.0M to $249.0M, cash from operations was $-245.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged 72.3% over five years, and was -343.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Novavax, Inc. (NVAX) — frequently asked questions